JW to conduct Phase I trial for new anticancer medicine

Published: 2011-05-13 06:57:00
Updated: 2011-05-13 06:57:00
JW Pharmaceutical has recently announced that it will conduct Phase I clinical trial for CWP231A, a candidate anticancer medicine that interrupts biochemical signals to eradicate leukemia stem cells without affecting normal cells, in the United States within this month.

Last month, the company...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.